Your browser doesn't support javascript.
Co-display of diverse spike proteins on nanoparticles broadens sarbecovirus neutralizing antibody responses.
Brinkkemper, Mitch; Veth, Tim S; Brouwer, Philip J M; Turner, Hannah; Poniman, Meliawati; Burger, Judith A; Bouhuijs, Joey H; Olijhoek, Wouter; Bontjer, Ilja; Snitselaar, Jonne L; Caniels, Tom G; van der Linden, Cynthia A; Ravichandran, Rashmi; Villaudy, Julien; van der Velden, Yme U; Sliepen, Kwinten; van Gils, Marit J; Ward, Andrew B; King, Neil P; Heck, Albert J R; Sanders, Rogier W.
  • Brinkkemper M; Amsterdam UMC, location University of Amsterdam, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.
  • Veth TS; Amsterdam Institute for Infection and Immunity, Infectious Diseases, Amsterdam, the Netherlands.
  • Brouwer PJM; Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, University of Utrecht, Padualaan 8, 3584 CH Utrecht, the Netherlands.
  • Turner H; Netherlands Proteomics Center, Padualaan 8, 3584 CH Utrecht, the Netherlands.
  • Poniman M; Amsterdam UMC, location University of Amsterdam, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.
  • Burger JA; Amsterdam Institute for Infection and Immunity, Infectious Diseases, Amsterdam, the Netherlands.
  • Bouhuijs JH; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
  • Olijhoek W; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
  • Bontjer I; Amsterdam UMC, location University of Amsterdam, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.
  • Snitselaar JL; Amsterdam Institute for Infection and Immunity, Infectious Diseases, Amsterdam, the Netherlands.
  • Caniels TG; Amsterdam UMC, location University of Amsterdam, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.
  • van der Linden CA; Amsterdam Institute for Infection and Immunity, Infectious Diseases, Amsterdam, the Netherlands.
  • Ravichandran R; Amsterdam UMC, location University of Amsterdam, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.
  • Villaudy J; Amsterdam Institute for Infection and Immunity, Infectious Diseases, Amsterdam, the Netherlands.
  • van der Velden YU; Amsterdam UMC, location University of Amsterdam, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.
  • Sliepen K; Amsterdam Institute for Infection and Immunity, Infectious Diseases, Amsterdam, the Netherlands.
  • van Gils MJ; Amsterdam UMC, location University of Amsterdam, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.
  • Ward AB; Amsterdam Institute for Infection and Immunity, Infectious Diseases, Amsterdam, the Netherlands.
  • King NP; Amsterdam UMC, location University of Amsterdam, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.
  • Heck AJR; Amsterdam Institute for Infection and Immunity, Infectious Diseases, Amsterdam, the Netherlands.
  • Sanders RW; Amsterdam UMC, location University of Amsterdam, Department of Medical Microbiology and Infection Prevention, Laboratory of Experimental Virology, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.
iScience ; 25(12): 105649, 2022 Dec 22.
Article in English | MEDLINE | ID: covidwho-2122550
ABSTRACT
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants poses continuous challenges in combating the virus. Here, we describe vaccination strategies to broaden SARS-CoV-2 and sarbecovirus immunity by combining spike proteins based on different viruses or viral strains displayed on two-component protein nanoparticles. First, we combined spike proteins based on ancestral and Beta SARS-CoV-2 strains to broaden SARS-CoV-2 immune responses. Inclusion of Beta spike improved neutralizing antibody responses against SARS-CoV-2 Beta, Gamma, and Omicron BA.1 and BA.4/5. A third vaccination with ancestral SARS-CoV-2 spike also improved cross-neutralizing antibody responses against SARS-CoV-2 variants, in particular against the Omicron sublineages. Second, we combined SARS-CoV and SARS-CoV-2 spike proteins to broaden sarbecovirus immune responses. Adding SARS-CoV spike to a SARS-CoV-2 spike vaccine improved neutralizing responses against SARS-CoV and SARS-like bat sarbecoviruses SHC014 and WIV1. These results should inform the development of broadly active SARS-CoV-2 and pan-sarbecovirus vaccines and highlight the versatility of two-component nanoparticles for displaying diverse antigens.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Randomized controlled trials Topics: Vaccines / Variants Language: English Journal: IScience Year: 2022 Document Type: Article Affiliation country: J.isci.2022.105649

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Randomized controlled trials Topics: Vaccines / Variants Language: English Journal: IScience Year: 2022 Document Type: Article Affiliation country: J.isci.2022.105649